Library / Peptides / Immune Support / Vilon
No human data · Grade D

Vilon

Vilon (Lys-Glu Dipeptide Bioregulator)
Evidence
No Human Data
Route
Oral or Sublingual
Frequency
Once daily
Category
Immune Support
TL;DR
Vilon is a two-amino-acid peptide from a Russian research program claiming broad immune and anti-aging benefits. The scientific evidence supporting it comes almost entirely from the group that developed it and has not been independently verified in peer-reviewed trials. Without independent human clinical data, it is impossible to assess whether it works or is safe. There are better-studied immune modulators available.
Part 01 · How it works

Mechanism.

Vilon is a synthetic dipeptide (Lys-Glu) developed by Vladimir Khavinson as a bioregulator peptide purported to derive from bone marrow and modulate immune function. It is one of the simplest Khavinson peptides and is theorized to have broad immunomodulatory and anti-aging properties. Like other Khavinson bioregulators, it lacks peer-reviewed independent clinical validation outside of Russian literature.

Vilon is one of the simplest possible signaling peptides — just two amino acids — supposedly acting like a two-letter text message to immune cells: 'wake up and regulate.' Whether immune cells actually receive and respond to this message in a meaningful way in humans remains scientifically unconfirmed.

Mechanism · technical
Vilon is proposed to function through Khavinson's bioregulator peptide theory — the dipeptide Lys-Glu supposedly binds to specific DNA promoter sequences in immune cells, modulating transcription of immune regulatory genes. In vitro studies from the Khavinson group report effects on NK cell activity, lymphocyte proliferation, and cytokine production. The dipeptide may also have direct cell-signaling effects via surface receptor interactions.
Part 02 · Dosing & administration

How it's taken.

Values below describe how Vilon has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
10-20 mg oral or sublingual
Oral or Sublingual · Once daily
Duration
10-20 day cycles, repeated every 3-6 months

Khavinson dipeptide (Lys-Glu) bioregulator for thymus. Simplest of the Khavinson bioregulators. Based on Russian protocols. No FDA-approved indication.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
No peer-reviewed clinical safety data available. Risks are unknown. As a dipeptide it may be largely degraded by GI proteases if taken orally. Contamination risk from unregulated sources.
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to vilon (Lys-Glu) or any component
×
Organ transplant recipients on immunosuppression
×
Active autoimmune disease in flare
Interactions
Immunosuppressants
Vilon is a thymic bioregulator that may stimulate immune function; could oppose immunosuppressive therapy
Moderate
Immune checkpoint inhibitors
Theoretical additive immune activation
Minor
Corticosteroids
High-dose corticosteroids may reduce vilon's immunostimulatory efficacy
Minor
Labs to monitor
CBC with Differential
Baseline and at end of cycle
Monitor immune parameters (thymic bioregulator)
T-Cell Subsets (CD4, CD8)
Baseline and at end of cycle
Vilon targets thymic/immune function
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2000
0
Vilon (Lys-Glu) effects on immune cell function: in vitro studies
Khavinson group in vitro studies reported that Vilon enhanced NK cell cytotoxicity and lymphocyte proliferative responses, and modulated IL-2 production in cultured human lymphocytes.
In vitro only. Exclusively from originating research group. Not independently replicated. In vitro immune effects do not predict in vivo or clinical outcomes.
02
2010
0
Peptide bioregulators in gerontology: Khavinson's synthesis of Russian clinical experience
A comprehensive review by Khavinson describes Vilon and related dipeptides as having favorable effects on longevity and immune biomarkers in elderly cohorts, though without controlled trial data.
Author is developer and primary researcher. No independent replication. Review quality does not meet international evidence standards.
PMID 20506235 ↗
Part 05 · Cost & access

Where you can get it.

Regulatory status
Not approved by FDA or EMA. Not a registered pharmaceutical in Western countries. Sold as a research peptide or longevity supplement in some markets. Regulatory status in Russia differs.
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment

Questions to bring.

01
Are there any peer-reviewed human clinical trials of Vilon outside of Russian research groups?
02
What purity and safety standards apply to Vilon sources available to consumers?
03
Given the lack of independent evidence, what are the risks of this compound versus established immune modulators?
04
Could a simple dipeptide survive oral administration or does it require injection?